At the heart of this work are telomeres, which are protective caps at the ends of our DNA. In people with pulmonary fibrosis, these telomeres are often unusually short, which pushes lung cells into a worn-out, inactive state known as senescence.

Dr. Jia Li Ye under the supervision of Dr. Chatterjee and Prof. Bär set out to counter this by temporarily boosting telomerase – the enzyme that rebuilds telomeres. Instead of using traditional gene therapy, the team used a newer approach based on modified messenger RNA. This allows cells to briefly produce telomerase without permanently altering their DNA.

In lab-grown human lung cells, the treatment successfully reactivated telomerase, reduced DNA damage, and improved the cells’ ability to grow and divide. Importantly, the effect was temporary, which may reduce safety concerns linked to long-term telomerase activation.

The researchers then tested the therapy in living slices of lung tissue taken from patients with advanced pulmonary fibrosis. Even a single treatment reduced markers of cellular aging and lowered signals linked to inflammation and scarring. These findings suggest the therapy could not only slow fibrosis but potentially help repair damaged tissue.

The study also explored a more stable circular form of RNA, which prolonged the treatment’s effects and further improved telomere length. This could make future therapies a lot more efficient.

The team’s research highlights a compelling direction for treating age-related lung diseases. By targeting the underlying biology of cellular aging, the research team of Bär and Chatterjee is opening the door to therapies that aim not just to manage pulmonary fibrosis, but to fundamentally change how it progresses.